Skip to Content
  1. Authors
  2. Michael Waterhouse

Michael Waterhouse

Michael Waterhouse is a healthcare strategist for Morningstar.


Although we think the narrow-moat drugmaker looks undervalued, the company continues to face significant challenges as it transitions to a new CEO and from the potential upcoming competition on Copaxone.

Distributors Henry Schein and Patterson should be able to maintain their competitive advantages over the long run and deserve a spot on investors' watchlists.